Biosimilars Canada Boss Calls For Ontario Switching Policy
Jim Keon Urges Ontario To Follow Other Provinces And Adopt Biosimilar Switching Program
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.
You may also be interested in...
The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.
The Canadian Northwest Territories have become the fifth jurisdiction and first territorial government to implement a biosimilar switching policy.
Patients taking Humalog and NovoRapid will have six months to switch to their biosimilar equivalents after British Columbia added the rapid-acting insulins to its biosimilar switching policy.